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Abstract 
Background: Gamma-glutamyltransferase (GGT) is a well-established independent risk factor for cardiovascular mor-
tality related to atherosclerotic disease. Four GGT fractions have been identified in plasma, but only b-GGT fraction 
accumulates in atherosclerotic plaques, and correlates with other histological markers of vulnerability. The present 
study was aimed to evaluate whether macrophagic lineage cells may provide a source of b-GGT within the athero-
sclerotic plaque.
Methods: GGT expression and release were studied in human monocytes isolated from peripheral blood of healthy 
donors. The growth factors GM-CSF and M-CSF were used to induce differentiation into M1-like and M2-like mac-
rophages, respectively. Plaque GGT was investigated in tissue samples obtained from patients undergoing carotid 
endoarterectomy.
Results: We found that M1-like macrophages express higher levels of GGT as compared to M2-like, and that both 
monocytes and M1-like macrophages—but not M2-like—are able to release the b-GGT fraction upon activation with 
pro-inflammatory stimuli. Western blot analysis of b-GGT extracted from plaques confirmed the presence of a GGT 
immunoreactive peptide coincident with that of macrophages.
Conclusions: Our data indicate that macrophages characterized by a pro-inflammatory phenotype may contribute 
to intra-plaque accumulation of b-GGT, which in turn may play a role in the progression of atherosclerosis by modu-
lating inflammatory processes and favouring plaque instability.
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Background
Monocyte/macrophage lineage cells represent one of 
the main cellular components of atherosclerotic lesions. 
Atherosclerosis is a progressive and chronic inflamma-
tory disease characterized by cellular and molecular 
alterations within the arterial wall which lead to lumen 
narrowing and/or to plaque rupture with superimposed 
acute thrombosis [1, 2]. Such condition is by far the 
most frequent underlying cause of coronary, carotid and 
peripheral arterial disease [3]. The inflammatory reac-
tions taking place in plaques implicate highly complex 
processes that are still not completely understood. How-
ever, it is known that the recruitment of leukocytes play 
a key role in these events, and monocytes in particular 
invade atherosclerotic lesions and differentiate into mac-
rophages. The heterogeneity of macrophages detect-
able in atherosclerotic lesions has been a topic of great 
interest lately, with particular reference to the two major 
macrophage subpopulations involved in pro-inflamma-
tory processes (“M1” phenotype) and in resolution and 
repair (“M2” phenotype), respectively. Actually, M1 and 
M2 macrophages are thought to represent the extreme 
polarization phenotypes of a continuum of pro- and 
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anti-inflammatory macrophages all simultaneously pre-
sent in atherosclerotic lesions [4–6]. M1 macrophages 
were demonstrated to be the predominant phenotype in 
rupture prone shoulder regions of human plaques, while 
M2 macrophages-associated markers were predominant 
in the adventitia [7]. On the other hand M2 macrophages 
were identified in more stable cell-rich areas, away from 
the lipid core of human atherosclerotic plaques [8, 9]. 
It was suggested that—in response to the changing 
environment in developing atherosclerotic plaques—
macrophages may shift transiently between different phe-
notypes. Nevertheless a number of questions remain to 
be answered, e.g. little is known about the propensity of 
individual macrophage phenotypes to become foam cells, 
even if some reports suggest that both M1 and/or M2 
macrophages may be foam cell precursors [5, 10].
Epidemiological studies showed that total serum 
gamma-glutamyltransferase (GGT) activity is an inde-
pendent risk factor for cardiovascular mortality related 
to atherosclerotic disease [11] and a correlation between 
plasma GGT levels and the presence of multivessel dis-
ease has been proposed [12]. We recently identified four 
different GGT fractions in human blood [13] and an 
association between the fraction with highest molecu-
lar weight (b-GGT) with known cardiovascular risk fac-
tors—such as LDL-cholesterol, triglycerides, glucose 
and C-reactive protein—was demonstrated [14]. More 
recently, a first characterization revealed that b-GGT 
consists of membrane microvesicles with physical prop-
erties resembling those of exosomes [15].
Importantly, b-GGT has been detected also inside ath-
erosclerotic plaques [16] and it has been suggested that 
this may be a factor in pathogenesis of atherosclerosis. 
Indeed, GGT enzyme activity is involved in the modu-
lation of inflammatory mediators such as leukotrienes 
[17] and S-nitrosoglutathione (GSNO) [18] and it has 
been repeatedly documented that in the presence of glu-
tathione and transition metal cations (in particular Fe3+ 
and Cu2+), GGT activity is able to trigger the production 
of reactive oxygen species (superoxide, hydrogen perox-
ide), thus promoting LDL oxidation and other pro-oxi-
dant reactions potentially involved in the progression of 
atherosclerotic lesions [19–21]. The necrotic core of the 
plaque, where both GGT [19, 20] and iron [22] are pre-
sent at adequate concentrations, represents an environ-
ment favourable to the evolution of such reactions.
Human mononuclear cells have long been known to 
express GGT activity [23, 24] and GGT-positive CD68+ 
macrophage-derived foam cells are present in the inti-
mal layers of human atherosclerotic plaques [25, 26]. The 
levels of intra-plaque b-GGT activity were demonstrated 
to correlate with both plasma b-GGT and levels of mac-
rophagic infiltration, a histological marker of plaque 
vulnerability [27]. Against this background, the aim of 
the present study was to assess whether monocytes/mac-
rophages may represent a source of b-GGT within the 
atherosclerotic plaque.
Methods
Chemicals
Unless otherwise indicated, all reagents were from Sigma 
Chemical Co. (St. Louis, MO, USA). Recombinant human 
cytokines and growth factors were purchased from Pep-
roTech (London, UK).
Ethics, consent and permissions
The study was approved by the Institutional Ethics Com-
mittee of the University Hospital of Pisa, and conformed 
to the Declaration of Helsinki. Patients gave their verbal 
informed consent to participate and the data were ana-
lysed anonymously.
Isolation and activation of monocytes
Human peripheral blood mononuclear cells (PBMCs) 
were isolated by Histopaque®-1077 density centrifuga-
tion from the blood of healthy donors. Monocytes were 
enriched by plating (10  ×  106 cells/wells) PBMCs in 
6-well plates (Sarstedt) with RPMI 1640 medium con-
taining 2  mmol/L l-glutamine and 10  % v/v fetal calf 
serum, the latter ultracentrifuged (100,000×g, 120  min, 
4 °C) before addition to remove serum-associated b-GGT 
(data not shown). After 2  h, non-adherent cells were 
removed and adherent cells were washed five times with 
RPMI 1640. Cytospin preparations of trypsinized cells 
were prepared to evaluate the purity of adherent mono-
cytes (74.5 % ± 3.4 monocytes, 25.0 % ± 3.6 lymphocytes, 
1.1 % ± 0.4 neutrophils; n = 8). Monocytes-enriched cell 
preparations were then incubated with ionomycin (1 μM, 
15 min), LPS (5 μg/ml, 24 h) or a combination of TNFα/
IL-1β (both 10 ng/ml, 24 h), as described by others [28–
30]. All cells were kept in a humidified incubator with 5 % 
CO2/95  % air and cell viability was assessed by Trypan 
blue exclusion. Finally media were collected and centri-
fuged at 300×g (5 min, 4 °C) and 10,000×g (10 min, 4 °C) 
before GGT determinations. Further details are reported 
in the figure legends.
Polarization of monocytes into M1‑like or M2‑like 
phenotype
In vitro differentiation of monocytes into macrophages 
with properties similar to M1 and M2 cells (“M1-like” 
and “M2-like”, respectively) was obtained as repeat-
edly described [10, 31–34]. Briefly, PBMCs isolated by 
Histopaque®-1077 density centrifugation were left to 
adhere for 24  h in RPMI 1640 medium integrated with 
2  mmol/L l-glutamine, 100  U/ml penicillin, 100  μg/ml 
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streptomycin and 10  % v/v fetal calf serum. After 24  h, 
non-adherent cells were removed, while adherent cells 
were cultured for additional 6 days in complete medium 
integrated with 50  ng/ml recombinant human granulo-
cyte/macrophage colony stimulating factor (GM-CSF) 
or with 50  ng/ml macrophage colony stimulating factor 
(M-CSF), respectively. Where indicated, cells were incu-
bated for additional 24  h with a combination of TNFα/
IL-1β (both 10 ng/ml) [28–30] and media were collected 
as described above.
In another set of experiments, adherent monocytes 
were incubated with M-CSF for 6  days in the presence 
of a mouse anti-IL10 antibody (1 μg/ml; Abcam) or the 
corresponding isotype control (1 μg/ml; Abcam). Other 
experiments were finally performed by incubating adher-
ent monocytes with TNFα (10  ng/ml) and/or IL-10 
(20  ng/ml) in complete medium for 48  h. Where indi-
cated, cells were pre-treated (20  min) with IL-10, then 
TNFα was added to incubation media. Cell viability was 
assessed by Trypan blue exclusion. Further details are 
reported in the figure legends.
Plaques and monocytes staining
Samples of carotid plaques were from patients undergo-
ing carotid endarterectomy at the General and Vascular 
Surgery (University Hospital, Pisa, Italy) and were already 
fully characterized [27]. The patients were asymptomatic, 
since endarterectomy is recommended in case of severe 
carotid artery stenosis (>70 %) even in absence of neuro-
logical symptoms [35]. Surgically excised carotid plaques 
were collected on ice and dissected into 5-mm segments, 
then a segment of the plaque was frozen at −20  °C in 
Optimal Cutting Temperature (OCT) medium for in situ 
evaluation of enzymatic activity. Plaque sections were 
stained as described [27]. Briefly, serial 3 μm paraffin sec-
tions were stained with hematoxylin-eosin and Masson’s 
trichrome method. Immunohistochemistry was per-
formed on adjacent paraffin-embedded sections. Mac-
rophages were identified by immunoperoxidase staining 
by using a specific monoclonal antibody raised against 
CD68 antigen (Dakopatts, Glostrup, Denmark) and the 
immunoreaction was visualized by 3-diaminobenzidine 
substrate. GGT immunostaining was performed by using 
a previously characterized polyclonal antibody directed 
against the heavy chain of human GGT antibody at the 
appropriate dilution (1:1600) [36]. Basing on plaque his-
tology [27], two (#1, #2) representative thin-cap fibroath-
eromas with large necrotic core and medium–high 
macrophage infiltration score, and one (#3) stable, thick-
cap fibroatheroma with small necrotic scores and low 
macrophage infiltration score, were selected (Table 1).
Cytochemical staining for GGT activity was per-
formed on air-dried buffy coat films fixed in a phosphate-
buffered acetone formaldehyde mixture (PBAF) and 
incubated with GGT substrate gamma-glutamyl-4-meth-
oxy-2-naphtylamide and Fast Garnet GBC, as previously 
described [24]. Nuclei were counterstained with methyl 
green.
Microvesicles isolation
Portions of plaque tissue were snap-frozen in liquid nitro-
gen, mechanically disrupted and homogenized in 5 % vol-
ume of cold hypotonic buffer (PBS diluted 10 folds) using 
a Potter homogenizer. Isolation of microparticles and 
exosomes from monocytes/macrophages supernatants 
as well as from homogenates of atherosclerotic lesions 
was performed by a differential centrifugation proce-
dure [15]. Samples were first centrifuged at 2000×g for 
10  min at 4  °C, then supernatants were centrifuged at 
10,000×g (45  min, 4  °C) to remove large debris. Again, 
supernatants were collected, transferred into ultracentri-
fuge tubes and centrifuged at 100,000×g (120 min, 4 °C). 
Pellets were then washed (100,000×g, 120 min, 4 °C) and 
finally resuspended in physiological saline.
Western blot analysis
For western blot determinations of GGT, isolated mono-
cytes, lymphocytes, platelets and cultured endothe-
lial HMEC-1 cells—harvested in hypotonic lysis buffer 
(10 mM Tris–HCl, pH 7.8)—or plaque derived exosomes 
were used. Non-adherent lymphocytes were isolated 
from plated PBMCs, whereas platelets were obtained 
from buffy-coat derived platelet concentrates. All 
samples were thoroughly washed in order to remove 
Table 1 Histological features of the selected plaques used
N. Cap thickness Necrotic core CD68+ macrophages Fibrous tissue Calcification Intra‑plaque activities 
(mU/g tissue)
b‑GGT Total GGT
#1 Thin and ulcerated High Medium Low Low 28.89 100.73
#2 Thin and ulcerated High Medium Low Low 14.61 47.02
#3 Thick Medium Low Medium High 9.43 35.58
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contaminating plasma GGT. Endothelial HMEC-1 cells 
were grown in MCDB 131 medium (Life Technologies) 
supplemented with 1  µg/ml hydrocortisone, 10  ng/ml 
EGF (Life Technologies) and 10  % v/v fetal calf serum, 
and cultured at 37 °C in a 5 %/95 % CO2/air atmosphere.
All samples were separated by 8 % SDS-PAGE [37] and 
incubated with rabbit anti-GGT IgG directed against the 
C-terminal 20 amino acids of human GGT heavy chain 
prepared as described [36]. Visualization of protein 
bands was obtained using a horseradish peroxidase-con-
jugated anti-rabbit IgG antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) and the ECL detection system 
(Roche, Basel, Switzerland). Bands were analyzed with a 
Bio-Rad ChemiDoc apparatus equipped with the Quan-
tityOne software.
Fractional GGT analysis by high‑performance gel filtration 
chromatography
Determination of GGT fractions was performed as previ-
ously described [13, 38] by a FPLC system (AKTA-puri-
fied-10, GE-Healthcare). Separation and quantification of 
GGT fractions was performed by gel-filtration chroma-
tography (Superose 6 10/300, GE Healthcare) followed 
by post-column injection of the fluorescent substrate 
gamma-glutamyl-7-amido-4-methylcoumarin. Intensity 
of the fluorescence signal was expressed in arbitrary fluo-
rescence units (f.u.) and the area under chromatographic 
peaks was proportional to GGT activity. The elution vol-
ume for b-GGT fraction is 12.9  ml, corresponding to a 
molecular weight (MW) of 2000 kDa [13].
Other determinations
GGT activity was determined according to Huseby and 
Strömme [39]. Cytokines were measured using specific 
enzyme-linked immunosorbent assay kits (TNF-α, R&D 
Systems; IL-6 and IL-10, Affymetrix eBioscience) accord-
ing to the manufacturer’s instructions. Protein content 
was determined by the Bradford’s method using the Bio-
Rad protein assay reagent. Statistical analysis of data was 
performed by Student’s t test for paired observations and 
one-way ANOVA with Newman–Keuls test for multiple 
comparisons.
Results
Monocytes activation
In agreement with earlier evidence [24], different levels 
of GGT activity were detected when monocytes isolated 
from the blood of healthy donors were stained for the 
enzyme (Fig.  1a), and a mean value of 10.1  ±  2.0  mU/
mg of protein in the whole homogenate was calculated. 
In order to understand whether such cells were able to 
release GGT, isolated monocytes were exposed to acti-
vating substances and GGT activity was measured in the 
incubation media. As reported in Fig.  1, both the com-
bination of pro-inflammatory cytokines TNFα/IL-1β 
(Fig.  1b) and bacterial lipopolysaccharide (LPS; Fig.  1c) 
significantly increased (p  <  0.05) GGT activity in the 
incubation media as compared to controls. In a separate 
set of experiments also the calcium ionophore ionomycin 
induced a significant (p  <  0.05) release of GGT activity 
in the incubation media (data not shown). GGT activ-
ity was also detected in the media of the corresponding 
control samples (Fig. 1b, c), possibly ensuing from a weak 
activation of monocytes during isolation/incubation pro-
cedures. As regard cell-associated GGT activity, TNFα/
IL-1β treatment did not produce any appreciable effect 
(Fig. 1d), whereas a significant decrease was induced by 
LPS (Fig. 1e; p < 0.05).
Macrophages activation
M1- and M2-like macrophages were obtained by incu-
bating aliquots of monocytes (isolated from the same 
buffy coat) with GM-CSF or M-CSF, respectively. As 
previously described [32], after 6  days of culture the 
majority of M1-like macrophages presented with a clas-
sical adherent, “fried egg” morphology, whereas M2-like 
macrophages primarily presented with a stretched, 
spindle-like morphology (data not shown). The analy-
sis of cytokines concentration in culture media revealed 
significantly (p  <  0.01) higher levels of TNFα and IL-6 
(Fig. 2a, b) and lower (p < 0.05) levels of IL-10 (Fig. 2c) 
for M1-like as compared to M2-like macrophages. 
M1-like macrophages showed also significantly 
(p < 0.005) higher levels of cell associated GGT activity 
(Fig.  3a) and protein (Fig.  3b) as compared to M2-like 
macrophages. SDS-PAGE analysis revealed that the 
GGT heavy subunit presented with the same apparent 
MW in both differentiated macrophages and monocytes 
(Fig. 3b).
The exposure to pro-inflammatory cytokines TNFα/
IL-1β induced a significant increase (p  <  0.05) of both 
released (Fig. 4a) and cell-associated GGT (Fig. 4c) only 
in M1-like macrophages, whereas no appreciable effect 
was detectable in M2-like cells (Fig. 4b, d).
Regulation of GGT expression in M1‑like and M2‑like 
macrophages
In order to characterize the possible mechanisms under-
lying the lower expression of GGT in M2-like mac-
rophages, we evaluated the involvement of IL-10. As 
expected, 48  h incubation of monocytes with TNFα 
resulted in increased levels of cellular GGT activity 
(Fig. 5a) and protein (data not shown), but this effect was 
completely abolished when also IL-10 was added to incu-
bation media (Fig. 5a). In a separate set of experiments, 
M2-like macrophages were incubated during their 
Page 5 of 13Belcastro et al. J Transl Med  (2015) 13:325 
differentiation with an anti-IL-10 antibody. As shown in 
Fig. 5b the addition of the blocking antibody was associ-
ated with induction of significantly higher levels of both 
GGT activity (p < 0.05) and protein (data not shown).
Release of b‑GGT fraction in monocytes/macrophages 
supernatants
Incubation media from activated monocytes and M1-like 
macrophages were ultracentrifuged at 100,000×g 
and incubation media were analyzed by gel-filtration 
chromatography. As shown in Fig. 6 a peak correspond-
ing to the b-GGT fraction was detected in the incuba-
tion media of both monocytes (Fig.  6a) and M1-like 
macrophages (Fig. 6b). In both cases, the exposure to the 
pro-inflammatory cytokines TNFα/IL-1β increased the 
release of b-GGT.
GGT expression in atherosclerotic plaque
In agreement with previous evidence [26, 27], the immu-
nohistochemical staining of plaques sections revealed the 
Fig. 1 Cytochemical staining for GGT enzyme activity expressed in activated monocytes. Monocytes from the blood of healthy donors expressing 
different levels of GGT activity. The azo-dye reaction product (reddish-brown) varies in intensity from slight to very strong, resulting in diffuse staining 
or granular positivity. Nuclei were counterstained with methyl green. Original magnification: ×100 (a). Monocytes isolated from fresh buffy coats 
were incubated in the presence of TNFα/IL-1β (both 10 ng/ml; 24 h) or LPS (5 μg/ml; 24 h). GGT activity was measured in the 10,000×g centrifuged 
supernatants (b, c) and in cellular homogenates (d, e). Results—expressed as mU/mg of cellular proteins—are mean ± SD of five to nine separate 
determinations. Data were analyzed by Student’s t test for paired data; *p < 0.05 as compared with the corresponding control
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presence of variable amounts of immunoreactive GGT, 
mainly localized to areas corresponding to necrotic core 
and macrophage-rich sites (Fig. 7).
The fractional GGT analysis of plaque homogen-
ates (Table  1) confirmed the presence of a major peak 
corresponding to the b-GGT fraction (Fig.  8a–c). In 
order to further characterize the properties of such 
fraction, plaque b-GGT was isolated by ultracentrifu-
gation from all the selected samples, and the GGT pro-
tein was compared by SDS-PAGE with that expressed 
by monocytes, lymphocytes, platelets and endothelial 
cell line HMEC-1 (Fig.  8d). Using a specific antibody 
against the heavy subunit of GGT, a single GGT band 
with the same apparent molecular weight was observed 
in monocytes, lymphocytes and platelets, while two 
bands were present in HMEC-1 cells, a heavier one and 
one slightly lighter than those observed in the other cell 
types. Plaques homogenates showed three bands: one 
comparable with the heavier band of HMEC-1, one with 
the same apparent MW of monocytes, lymphocytes and 
platelets, and one lighter than all the other observed 
bands. Interestingly, the second band was clearly detect-
able only in samples with a higher macrophage score (#1 
and #2).
Discussion
GGT activity is a well-established independent risk fac-
tor for coronary and cerebrovascular events both in 
unselected populations [11] and in patients with diag-
nosed coronary artery disease [12]. GGT activity has 
been detected inside human atherosclerotic plaques 
associated both to CD68+ macrophage-derived foam 
cells [25, 26] and to a microvesicles-like fraction called 
b-GGT [16, 27]. The b-GGT fraction is the heaviest of 
the four GGT fractions identified in plasma [38] and it 
is the sole identified within plaque homogenates [27]. In 
a recent study b-GGT has been demonstrated to con-
sist of membrane microvesicles [15], sharing the physi-
cal properties of exosomes. Interestingly, intra-plaque 
b-GGT activity correlates with the histological markers 
Fig. 2 Cytokines in the supernatant of monocyte-derived macrophages. Monocytes isolated from fresh buffy coats were incubated for 6 days in 
complete medium in the presence of GM-CSF (50 ng/ml) or M-CSF (50 ng/ml) in order to induce the differentiation into M1-like or M2-like mac-
rophages, respectively. Data represent levels of a TNFα, b IL-6 and c IL-10 in culture media on the sixth day of incubation. Results are mean ± SD of 
five separate determinations. Data are expressed as mU/mg of cellular proteins and were analyzed by Student’s t test for paired data; *p < 0.01 and 
**p < 0.05 as compared with the corresponding control
Fig. 3 Effects of GM-CSF and M-CSF exposure on cellular GGT 
expression. Monocytes isolated from fresh buffy coats were incu-
bated for 6 days in complete medium in the presence of GM-CSF 
(50 ng/ml) or M-CSF (50 ng/ml) in order to induce the differentiation 
into M1-like or M2-like macrophages, respectively. a Data are ratioes 
between GGT activities determined after differentiation and activi-
ties present in initial monocytes. The results of ten separate paired 
incubations are shown. Solid lines connect data pairs obtained with 
the same starting monocytes preparation. Statistical analysis was per-
formed by Student’s t test for paired data; *p = 0.0016. b Representa-
tive western blot analysis of GGT expression. Lane 1 monocytes; lane 2 
M1-like macrophages; lane 3 M2-like macrophages
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of plaque vulnerability—such as high macrophagic infil-
tration—as well as with levels of plasma b-GGT [17–27]. 
These pieces of evidence have prompted the need of 
identifying the origin of GGT accumulating inside ather-
osclerotic plaques, in order to better understand its role 
in plaque instability.
It was proposed that part of b-GGT present in ath-
erosclerotic plaques might derive from the bloodstream 
through damaged endothelium [16, 27]. On the other 
hand an endogenous release of b-GGT by cellular ele-
ments of plaque—such as macrophages—is also con-
ceivable. Indeed our results demonstrate that both 
monocytes (Figs.  1, 6) and pro-inflammatory M1-like 
macrophages (Figs. 4, 6) are able to release b-GGT upon 
activation. These results are in agreement with what 
already observed for neutrophils—whose contribute to 
inflammatory exudate b-GGT in cystic fibrosis airways 
has been assessed [37]—and adds evidence in support 
of the connection between GGT and inflammation. 
GGT is expressed by inflammatory cells [24] and its 
expression is induced by inflammatory cytokines (e.g. 
TNFα, IFNs) and oxidative stress. Two major inflamma-
tory mediators, cysteinyl-leukotriene LTC4 and S-nitro-
soglutathione, are GGT substrates, and it was even 
proposed that soluble GGT may effect a cytokine-like 
function [40].
The potential contribution of macrophages to plaque 
b-GGT accumulation was further investigated by SDS-
PAGE analysis of samples belonging to a previously 
characterized series of carotid plaques [27]. A single 
Fig. 4 GGT release by activated macrophages. Monocytes isolated from fresh buffy coats were incubated for 6 days in complete medium in the 
presence of GM-CSF (50 ng/ml) or M-CSF (50 ng/ml) in order to induce the differentiation into M1-like or M2-like macrophages, then they were 
incubated in the presence of TNFα/IL-1β (both 10 ng/ml) for additional 24 h. GGT activity was measured in the 10,000×g centrifuged supernatants 
(a, b) and in cellular homogenates (c, d). Results are mean ± SD of eight separate determinations. Data are expressed as mU/mg of cellular proteins 
and were analyzed by Student’s t test for paired data; *p < 0.05 as compared with the corresponding untreated control
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peak corresponding to b-GGT was detected in all the 
plaques studied (Fig.  8a–c), but SDS-PAGE analysis 
revealed a heterogeneous composition of such fraction 
(Fig.  8d). In this respect it should be considered that 
GGT protein is transcribed from a single gene (ggt1), 
nevertheless several distinct glycosylation forms have 
been described, resulting in different molecular weights 
[41]. It was also demonstrated that inflammatory cells 
present in the vessel wall might induce modifications 
in protein sialylation status [42]. The presence of dif-
ferent bands corresponding to distinct MWs (Fig.  8d) 
may thus reflect both a heterogeneous origin for intra-
plaque b-GGT as well as an intra-plaque modification 
of GGT protein (e.g. proteolysis, sialylation). SDS-
PAGE analysis nevertheless confirmed that inflam-
matory as well as endothelial cells might contribute to 
b-GGT accumulation within the atherosclerotic plaque. 
SDS-PAGE does not allow discriminating among differ-
ent “inflammatory” sources for b-GGT, and it is con-
ceivable that macrophages, lymphocytes and platelets 
all can contribute to intra-plaque b-GGT. In particu-
lar, the demonstrated correlation between intra-plaque 
b-GGT activity and the levels of macrophages infiltra-
tion [27] and the fact that both monocytes (Figs.  1, 6) 
and M1-like macrophages (Figs. 4, 6) are able to release 
b-GGT upon activation, suggest that macrophages play 
a major role in b-GGT accumulation inside the athero-
sclerotic plaque.
As previously observed for neutrophilic infiltrates in 
cystic fibrosis [37], b-GGT accumulation in the athero-
sclerotic plaque should not be interpreted as the mere 
epiphenomenon of an exogenous contribute (i.e., from 
the bloodstream), or as the effect of inflammation-
related oxidative stress. Rather, the expression and the 
release of b-GGT by macrophages may be considered as 
one of the effects associated with the immune response, 
possibly involved in the modulation of selected media-
tors (e.g. GSNO, leukotrienes). Moreover, in selected 
conditions GGT activity has been shown to promote 
the production of reactive oxygen species and other 
prooxidants, resulting in redox reactions potentially 
involved in the progression of atherosclerosis [19–21]. 
M1 macrophage content of atherosclerotic plaques is 
positively associated with increased inflammation and 
clinical incidence of ischemic stroke [9]. High num-
bers of M1 macrophages were detected in symptomatic 
plaques, whereas smaller numbers, predominantly 
staining for M2 macrophage markers, were detected 
in asymptomatic plaques [5, 7–9]. The higher levels 
of GGT expression and b-GGT release observed from 
M1-like macrophages may thus play a role in plaque 
instability.
Altogether, our data indicate that inflammatory con-
ditions are able to increase the expression and release 
of GGT enzyme, which in turn could play a role in 
modulating inflammation in the plaque environment. 
The higher cellular GGT expression in GM-CSF-
induced M1-like macrophages, as compared to M-CSF-
induced M2-like ones (Figs.  1a, b), appears to further 
support such hypothesis. Our data are in agreement 
with earlier evidence obtained with the human leu-
kemic cell line KG-1, where incubation with GM-CSF 
resulted in a significant increase in GGT enzyme activ-
ity, while M-CSF did not produce any appreciable effect 
[43]. As far as treatment of monocytes with GM-CSF 
and M-CSF it has been reported that both GM-CSF 
and M-CSF receptors activate Ras-dependent signal 
transduction pathways and are both capable of activat-
ing AP-1 [44]. GM-CSF [45] and to some extent M-CSF 
Fig. 5 Effects of TNFα and IL-10 on GGT expression in monocytes. 
a Freshly isolated monocytes were incubated with TNFα (10 ng/ml) 
and/or IL-10 (20 ng/ml) in complete medium for 48 h. Results are 
mean ± SD of eight separate determinations. Data are expressed as 
mU/mg of cellular proteins and were analyzed by one-way ANOVA 
with Newman–Keuls test for multiple comparisons; §p < 0.001 as 
compared to untreated control; *p < 0.001 as compared with TNFα-
treated samples. b Isolated monocytes were let to adhere for 24 h, 
then they were incubated with M-CSF (50 ng/ml) in the presence of 
an anti-IL10 antibody (1 μg/ml) or the corresponding isotype control 
for 6 days. Results are expressed as the ratio of GGT expressed by 
antibody-treated cells against M-CSF treatment alone (mean ± SD of 
seven separate determinations). Data were analyzed by Student’s t 
test for paired data; *p < 0.05
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Fig. 6 Gel filtration chromatography of b-GGT released by TNFα/IL-1-activated monocytes (a) and M1-like macrophages (b). Monocytes and GM-
CSF-differentiated M1-like macrophages were incubated with TNFα/IL-1β (both 10 ng/ml, 24 h), then supernatans were pooled and ultracentrifuged 
(100,000×g, 120 min, 4 °C). The resuspended final pellets were analyzed by gel filtration chromatography. Representative elution profiles of controls 
(dashed lines) and TNFα/IL-1β- activated cells (continuous line) are shown
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[46] are also known to modulate NF-κB activation, but 
with some important differences in terms of timing, 
duration and factors involved [47]. In agreement with 
previous evidence [33, 47], our M1-like macrophages 
produced higher levels of pro-inflammatory TNFα 
and IL-6 and lower levels of anti-inflammatory IL-10, 
whereas the opposite was observed with M2-like mac-
rophages (Fig. 2). Indeed, it has been proposed that Ras 
signalling is involved in GGT expression [48], and syn-
thesis of GGT mRNA is induced by cytokines—includ-
ing TNFα—through a NF-κB-dependent pathway [49, 
50]. The differential basal expression of cytokines in 
M1-like and M2-like macrophages could thus account 
for the differential GGT expression observed. Indeed 
TNFα was able to significantly increase GGT expres-
sion in monocytes, but this effect was inhibited in the 
presence of IL-10 (Fig.  5a), i.e. a cytokine known to 
inhibit NF-κB pathway [51, 52]. Accordingly, when 
monocytes were differentiated into M2-like cells, the 
addition of an anti-IL-10 antibody was associated to 
higher levels of GGT expression (Fig.  5b). The lack of 
GGT induction in M2-like cells following TNFα/IL-1β 
might be therefore explained by such inhibitory effect 
of endogenous IL-10 (Fig.  4c, d), whose expression is 
markedly higher in M2- as compared to M1-like cells 
[47]. These observations support the hypothesis that 
the balance of pro-inflammatory/anti-inflammatory 
cytokines such as TNFα and IL-10 may differentially 
modulate GGT expression.
Besides GM-CSF or M-CSF treatments, macrophage 
M1 or M2 phenotypes have also been obtained by 
other in vitro procedures. M-CSF was shown to induce 
M1 differentiation in the presence of IFN-γ and/or 
bacterial products such as LPS [53], whereas three dis-
tinct M2 subtypes were induced by treatments with 
IL-4 or IL-13 (“M2a” phenotype), or immune com-
plexes in combination with IL-1β or LPS (“M2b”), 
or IL-10, TGFβ and glucocorticoids (“M2c”) [54]. 
Interestingly, the ggt5 gene (formerly designated as 
GGTLA1/GGT-rel or GGL) was also recently shown 
to be highly expressed in GM-CSF differentiated mac-
rophages [33]. GGT5 is a member of GGT family sup-
posed to be mainly responsible for the conversion of 
LTC4 to LTD4 [55].
Conclusions
The results of the present study indicate that mac-
rophages characterized by a pro-inflammatory phe-
notype can release b-GGT and contribute thus to its 
accumulation inside atherosclerotic plaques. Our obser-
vations may explain the existing association between 
b-GGT activity in thin-cap fibroatheromas and greater 
macrophage infiltration [27]. Further studies are however 
Fig. 7 GGT expression in atherosclerotic plaques. A representative 
thin cap fibroatheroma without ulceration is shown. Masson’s tri-
chrome staining (a; blue collagen fibers; red cytoplasm; black nuclei); 
immunohistochemistry for GGT protein (b) and macrophage-associ-
ated antigen CD68 (c). GGT and CD68 were localized by immunop-
eroxidase reaction with 3-diaminobenzidine as substrate, yielding a 
reddish-brown color. Immunoreactivities are mainly localized in the 
necrotic core (asterisk) extending just beneath the endothelial lining 
of the plaque (arrow). Sections were couterstained with haematoxy-
lin. Original magnification: 10x
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needed to fully identify the different sources of intra-
plaque b-GGT and their actual role in the pathogenesis/
progression of atherosclerosis.
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Fig. 8 Elution profile of GGT activity from whole homogenate of three selected plaque samples (a, b, c). Elution profile was obtained by molecular 
exclusion chromatography, and GGT activity was detected by an online post-column reaction in the presence of a fluorescent substrate. A major 
peak of activity eluting at 12.9 ml and corresponding to the b-GGT fraction is detectable. d Western blot analysis of GGT heavy chain in samples of 
isolated plaque b-GGT and other biological samples. Lanes 1–3 b-GGT from plaques #1–3, respectively; lane 4 monocytes; lane 5 HMEC-1 endothelial 
cells; lane 6 lymphocytes; lane 7 platelets
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